Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis

Authors:

Abstract
No abstract available
Funding Information
  • AstraZeneca
  • Merck Sharp and Dohme United Kingdom